With China’s Communist Party Secretary Xi Jinping now in his third term, his anti-graft probes are continuing—with millions of cases investigated since he took power in 2012. Recently, Beijing’s anti-corruption organs announced the investigation of multiple top officials from state-owned enterprises in finance as well as industries such as nuclear, petrochemicals, shipbuilding, and property development. Between March…

News Analysis Beijing’s consolidation of state-owned enterprises is picking up speed in its final stages. Experts say that this is a step backward and that the inefficient mega-state enterprises will only add to China’s economic decline. On Oct. 31, the State-owned Assets Supervision and Administration Commission of the State Council (SASAC) held a restructuring contract…

Commentary With the 20th congress of the Chinese Communist Party (CCP) starting on Oct.16, Xi Jinping’s re-election seems to be a given. In the face of a deteriorating economy, Xi’s government may go ahead with “one state-owned enterprise for one industry” and “national unified market,” an upgraded model of the planned economy, experts say. This…

On the eve of the twentieth Chinese Communist Party (CCP) Congress, authorities accelerated the construction of nuclear power stations, the energy base to support CCP-controlled mega corporations intended to outcompete their global peers. “It is an attempt of the CCP to create industry giants through state monopoly, and to participate in global competition,” Shi Shan,…

A recent wealth flaunting incident by a state-owned enterprise (SOE) employee, which has been a hot topic on the Chinese internet, has unexpectedly brought to light the underlying institutional corruption in the CCP. The young man in the spotlight was Zhou Jie. On July 25, someone broke the story that Zhou had posted messages on…

Less than two weeks after China’s conditional approval of Sinopharm’s COVID-19 vaccine, the chairman and a director at the state-owned drug company suddenly resigned on the same day for “personal reasons.” The unexpected news fueled public speculation and doubts over the quality of the Chinese-made vaccine. On Jan. 12, Sinopharm Group Co. issued two consecutive…